Processa Pharmaceuticals annual free cash flow
2012
2013
2014
2015
2016
2017
2018
2023
2024
2025
Processa Pharmaceuticals Free Cash Flow (FCF) History (PCSA)
Processa Pharmaceuticals reported −$12.2M in free cash flow for fiscal 2025, a decrease of $986,909 from the previous fiscal year.
View full Processa Pharmaceuticals company overviewProcessa Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$12.2M | −$986,909 | — | — |
| 2024 | 2024-12-31 | −$11.2M | −$3.2M | — | — |
| 2023 | 2023-12-31 | −$8.1M | — | — | — |
| 2018 | 2018-12-31 | −$3.7M | −$2.1M | — | — |
| 2017 | 2017-12-31 | −$1.7M | $503,573 | — | — |
| 2016 | 2016-12-31 | −$2.2M | −$1.3M | — | −43576.24% |
| 2015 | 2015-12-31 | −$873,305 | $1.8M | — | −769.94% |
| 2014 | 2014-12-31 | −$2.7M | −$136,202 | — | −2520.21% |
| 2013 | 2013-12-31 | −$2.6M | −$339,605 | — | −821.31% |
| 2012 | 2012-12-31 | −$2.2M | — | — | −1158.94% |
Processa Pharmaceuticals quarterly free cash flow
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.17
Q2.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2018 | 2018-12-31 | −$484,476 | — | — | — |
| Q3 2018 | 2018-09-30 | −$1.0M | — | — | — |
| Q2 2018 | 2018-06-30 | −$1.2M | −$866,948 | — | — |
| Q1 2018 | 2018-03-31 | −$1.1M | −$1.0M | — | — |
| Q2 2017 | 2017-06-30 | −$297,230 | — | — | — |
| Q1 2017 | 2017-03-31 | −$59,580 | — | — | — |
| Q4 2015 | 2015-12-31 | −$46,070 | $424,215 | — | — |
| Q3 2015 | 2015-09-30 | −$47,226 | $502,960 | — | −81.19% |
| Q2 2015 | 2015-06-30 | −$276,522 | $433,566 | — | −1379.85% |
| Q1 2015 | 2015-03-31 | −$503,487 | $498,023 | — | −1333.39% |
| Q4 2014 | 2014-12-31 | −$470,285 | −$7,746 | — | — |
| Q3 2014 | 2014-09-30 | −$550,186 | $179,479 | — | −1045.56% |
| Q2 2014 | 2014-06-30 | −$710,088 | $64,902 | — | −629.32% |
| Q1 2014 | 2014-03-31 | −$1.0M | −$402,261 | — | −4900.95% |
| Q4 2013 | 2013-12-31 | −$462,539 | — | — | −659.92% |
| Q3 2013 | 2013-09-30 | −$729,665 | $170,857 | — | −579.51% |
| Q2 2013 | 2013-06-30 | −$774,990 | — | — | −796.66% |
| Q1 2013 | 2013-03-31 | −$599,249 | — | — | −3121.09% |
| Q3 2012 | 2012-09-30 | −$900,522 | — | — | −1835.63% |
Processa Pharmaceuticals free cash flow growth trends
Processa Pharmaceuticals's latest reported quarter, Q4 2018, generated −$484,476 in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Processa Pharmaceuticals source filings ↗